TrialSignal
Clinical trial intelligence report
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 16, 2026
NCT ID
NCT02911948
Status
COMPLETED
Phase
Phase 3
Sponsor
Novo Nordisk A/S
Executive brief
Investment-Ready Snapshot
The trial investigates the efficacy and safety of insulin degludec/liraglutide versus insulin degludec in Japanese patients with inadequately controlled Type 2 Diabetes Mellitus (T2DM). Given the increasing prevalence of diabetes in Japan and the growing demand for effective treatment options, this dual-action therapy could capture significant market share. The competitive landscape includes established insulin therapies and GLP-1 receptor agonists, necessitating a robust differentiation strategy. Diligence should focus on regulatory pathways and potential reimbursement scenarios in Japan, where diabetes management is a priority.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02911948
Indication
Diabetes
Modality
small molecule
Target
Insulin receptors and GLP-1 receptors
Intervention
Insulin degludec/liraglutide, Insulin degludec
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.